Does CRP predict outcome in bipolar disorder in regular outpatient care?

International Journal of Bipolar Disorders

Volumn 4, Issue 1, 2016, Pages

  Balukova, Sonya M ^a   Haarman, Bartholomeus C M ^a   Riemersma van der Lek, Rixt F ^a   Schoevers, Robert A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biological markers; Bipolar disorder; C reactive protein; Historic cohort; Inflammation; Prognosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RAPID CYCLING BIPOLAR DISORDER;

EID: 84997565704     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-016-0055-3     Document Type: Article

References (38)

1. Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):21–36.
2. Becking K, Boschloo L, Vogelzangs N, Haarman BCM, Riemersma-van der Lek R, Penninx BWJH, et al. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry. 2013;3(10):e314.
3. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol. 2012;92(September):1–17.
4. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’Anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214–7.
5. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27:959–85.
6. Cunha AB, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Gonçalves CA, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300–4.
7. Dargél AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder. J Clin Psychiatry. 2015;76(2):142–50.
8. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25(5):1051–6.
9. Denicoff KD, Leverich GS, Nolen WA, Rush AJ, McElroy SL, Keck PE, et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med. 2000;30(6):1391–7.
10. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952–5.
11. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology. 2002;13(5):561–8.
12. Frecska E, Balla P, Falussy L, Ferencz A, Varga Z. The message of the survival curves: I. Composite analysis of long-term treatment studies in bipolar disorder. Neuropsychopharmacol Hungarica. 2012;14:155–64.
13. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.
14. Haarman BCM, Riemersma-Van der Lek RF, Burger H, Netkova M, Drexhage RC, Bootsman F, et al. Relationship between clinical features and inflammation-related monocyte gene expression in bipolar disorder—towards a better understanding of psychoimmunological interactions. Bipolar Disord. 2014;16(2):137–50.
15. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep. 2013;15(9):387.
16. Hamer M, Batty GD, Marmot MG, Singh-Manoux A, Kivimäki M. Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav Immun. 2011;25(1):168–73.
17. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608–16.
18. Hornig M, Goodman D, Kamoun M, Amsterdam J. Positive and negative acute phase proteins in affective subtypes. J Affect Disord. 1998;49(1):9–18.
19. Jacoby AS, Munkholm K, Vinberg M, Pedersen BK, Kessing LV. Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder—results from a prospective study. J Affect Disord. 2016;197:167–74.
20. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006;119(2):17–28.
21. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150(1–2):116–22.
22. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology. 1995;20(2):111–6.
23. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–11.
24. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.
25. Myint AM, Kim YKKY. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Neuropsychopharmacology Biol Psychiatry. 2013;48:304–13.
26. Nassar A, Azab A. Effects of lithium on inflammation. ACS Chem Neurosci. 2014;5:451–8.
27. O’Brien SM, Scott LV, Dinan TG. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry. 2006;188:449–52.
28. Palosuo T, Husman T, Koistinen J, Aho K. C-reactive protein in population samples. Acta Med Scand. 1986;220(2):175–9.
29. Perlis RH, Ostacher MJ, Marangell LB, Hongwei Z, Wisniewski SR, Ketter TA, et al. Predictors of recurrence in bipolar disorder: primary program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006;163(4):217–24.
30. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.
31. Rege S, Hodgkinson SJ. Immune dysregulation and autoimmunity in bipolar disorder: synthesis of the evidence and its clinical application. Aust N Z J Psychiatry. 2013;47(12):1136–51.
32. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7.
33. ten Have M, Vollebergh W, Bijl R, Nolen WA. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord. 2002;68(2–3):203–13.
34. Tsai S-Y, Chung K-H, Wu J-Y, Kuo C-J, Lee H-C, Huang S-H. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1–2):110–6.
35. Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res. 2015;228(3):386–92.
36. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5.
37. Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein and late-onset bipolar disorder in 78,809 individuals from the general population. Br J Psychiatry. 2016;208(2):138–45.
38. Ximenes JCM, de Oliveira Gonçalves D, Siqueira RMP, Neves KRT, Santos Cerqueira G, Correia AO, et al. Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(7):575–87.